RH
Ryan Hampton
August 01, 2023
The FDA also approved the first generic non-prescription naloxone drug in July 2023. The US Food and Drug Administration (FDA) approved the second over-the-counter (OTC) naloxone nasal spray product, RiVive (3mg) by non-profit pharmaceutical company Harm Reduction Therapeutics,...